Skip to main content

Table 1 Patient demographics, tumor characteristics, changes in retinal fluid, series of treatments and best corrected visual acuities of patients with circumscribed choroidal hemangioma

From: Retinal fluid changes and therapeutic effects in symptomatic circumscribed choroidal hemangioma patients: a long-term follow up study

Case No.

Age (years)/ Sex

FU (months)

Foveal distance (mm)

Initial LBD (mm)

Initial height (mm)

Initial retinal fluid pattern

IRF occurrence (Y/N)

Organized IRF pattern (Y/N) / Time point after initial presentation (mo)

Series of treatments (type-No.)

Initial BCVA (Snellen)

Highest BCVA during FU (Snellen)

BCVA change, Last BCVA (Snellen)

1

45/M

129

0

9

3.7

SRF only

Y

Y / 86

T3-A10-P1

0.5

0.8

Worsen, 0.01

2

66/F

123

0

10.1

4.6

SRF only

Y

N

T1-A2-T

0.05

0.1

Worsen, HM

3

57/M

114

0

9.4

3.5

SRF only

Y

N

T3-A2

0.2

0.2

Worsen, CF

4

52/F

110

5

9.3

4.9

SRF + IRF

Y

N

T1

0.025

0.025

Worsen, 0.01

5

63/M

96

1.5

8.27

3.22

SRF + IRF

Y

Y / 72

T2-A3-P1(E)

0.16

0.4

Worsen, 0.025

6

44/F

90

4

9.17

3.74

SRF only

Y

Y / 39

A2-P2-P1(E)

0.63

1.0

Improved, 0.8

7

48/F

79

0.75

11.07

4.77

SRF only

Y

Y / 71

A2-T1-P1-P1(E)

0.63

0.8

Worsen, 0.04

8

47/F

71

0

9.5

3.73

SRF only

N

N

A2-P1

0.2

0.63

Improved, 0.63

9

39/M

70

0

10.6

2.96

SRF only

Y

Y / 11

A2-P2-A3-P1(E)

0.63

0.8

Worsen, 0.16

10

51/F

65

2.2

8.4

3.2

SRF + IRF

Y

Y / 23

T2-A4-T1-A2

0.01

0.01

Worsen, CF

11

50/F

60

3

10.43

3.83

SRF + IRF

Y

N

P2

0.16

0.8

Improved, 0.8

12

60/M

59

1.3

7.99

2.27

Advanced CME

Y

Y / 0 (initial)

A2-P2-A1

0.63

0.8

Worsen, 0.4

13

52/F

59

1.6

5.24

1.95

SRF only

Y

N

P1(E)

0.63

1.0

stable

14

55/M

57

1

6.84

2.01

SRF only

Y

N

A5-P1(E)

0.2

0.63

Improved, 0.32

15

35/F

57

0

10.5

5.21

Advanced CME

Y

Y / 0 (initial)

A1

0.025

0.08

stable

16

35/F

55

2.9

10.53

4.73

SRF only

N

N

T2

0.05

0.2

Worsen, 0.013

17

54/M

54

0

11.86

3.64

Advanced CME

Y

Y / 0 (initial)

A1-P1-P1(E)-A3

0.4

0.5

Worsen, 0.063

18

57/M

36

0

8.91

2.24

SRF only

N

N

P1

0.2

0.32

Improved, 0.32

19

23/M

36

0.75

6.75

2.00

SRF only

N

N

P1-A2

0.32

0.63

Worsen, 0.04

20

40/M

36

3.5

8.73

3.37

SRF only

Y

N

P1- P1(E)

0.05

0.8

Improved, 0.32

21

47/M

34

0

7.36

2.91

SRF only

N

N

A1-P1(E)

0.013

0.32

Improved, 0.1

22

62/M

33

0

4.56

1.52

SRF only

N

N

P1

0.2

0.32

Stable

23

40/M

31

0

7.81

2.36

SRF only

N

N

P1-A2-P1

0.32

0.5

stable

24

63/M

33

3.2

7.29

2.64

SRF only

Y

N

A2-P2(E)

0.25

0.8

Improved, 0.5

25

49/M

42

0

8.14

2.98

SRF only

N

N

P1(E)

0.2

0.2

Worsen, 0.16

26

46/M

28

1.2

8.52

3.97

SRF only

N

N

P1-P1(E)

0.4

0.8

Improved, 0.5

  1. No. number, FU follow-up duration, LBD largest base diameter, SRF subretinal fluid, IRF intraretinal fluid, CME cystoid macula oedema
  2. BCVA best corrected visual acuity, M male, F female, HM hand motion, LP- no light perception, CF counting finger
  3. T transpupillary thermotherapy, P photodynamic therapy (typical dose), A intravitreal bevacizumab (Avastin) injection, P(E) enhanced dose P
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us